StreetInsider.com News Articles

Form SCHEDULE 13G/A FENNEC PHARMACEUTICALS Filed by: HIRSCHMAN ORIN

Mon, 19 Oct 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20261019/27201075.html

Form SCHEDULE 13G/A FENNEC PHARMACEUTICALS Filed by: HIRSCHMAN ORIN

Mon, 19 Oct 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20261019/27201075.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Sayad Pierre Sargis

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181116.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Sayad Pierre Sargis

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181116.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Hackman Jeffrey S.

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181115.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Hackman Jeffrey S.

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181115.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Cioffi Christiana Marie

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181109.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Cioffi Christiana Marie

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181109.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Evans Terry L

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181108.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Evans Terry L

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181108.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Andrade Robert

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181105.html

Form 4 FENNEC PHARMACEUTICALS For: Oct 12 Filed by: Andrade Robert

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181105.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Cioffi Christiana Marie

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135873.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Cioffi Christiana Marie

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135873.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Hackman Jeffrey S.

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135874.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Hackman Jeffrey S.

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135874.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Andrade Robert

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135878.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Andrade Robert

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135878.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Evans Terry L

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135885.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Evans Terry L

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135885.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Sayad Pierre Sargis

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135891.html

Form 4 FENNEC PHARMACEUTICALS For: Sep 30 Filed by: Sayad Pierre Sargis

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135891.html

Fennec Pharmaceuticals reports Pedmark hearing loss data in Japan

Thu, 17 Sep 2026 07:30:35 -0400

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) presented results from the Phase 2 STS-J01 clinical trial evaluating Pedmark (sodium thiosulfate injection) for reducing cisplatin-induced hearing loss in pediatric and adolescent and young adult patients with non-metastatic solid tumors in Japan. The data were presented at the 58th Annual International Society of Pediatric Oncology meeting in San Antonio, Texas.

The study enrolled 33 patients across 11 institutions in Japan. Among the 25 patients in the primary efficacy population, hearing loss as defined by the American Speech-Language-Hearing Association occurred in 24.0% of patients, compared with a prespecified historical benchmark of 56.4% (P=0.001). By

Fennec Pharmaceuticals reports Pedmark hearing loss data in Japan

Thu, 17 Sep 2026 07:30:35 -0400

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

Thu, 17 Sep 2026 07:30:00 -0400

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~

~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~

~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interval for Pediatric & Adolescent and Young Adult (AYA) Patients ~

~ Building Upon the Pivotal Children’s Oncology Group (COG) Protocol ACCL0431 & SIOPEL 6